Table 1 Antifungal consumption including voriconazole, caspofungine and fluconazole, expressed in defined daily dose (DDD) per 1000 patient-days, in 2019 and 2020
From: Impact of COVID-19 pandemic on antifungal consumption: a multicenter retrospective analysis
Antifungal | 2019 (DDD/1000 patient-days) | 2020 (DDD/1000 patient-days) | Variation in DDD/1000 patient-days (%) |
|---|---|---|---|
Systemic antifungals | |||
Whole hospital | 40.1 | 49.0 | + 22.2 |
ICU | 170.9 | 196.2 | + 14.8 |
Voriconazole | |||
Whole hospital | 6.2 | 8.7 | + 40.3 |
ICU | 29.8 | 48.8 | + 63.7 |
Caspofungine | |||
Whole hospital | 4.3 | 5.8 | + 34.9 |
ICU | 31.2 | 36.5 | + 17.0 |
Fluconazole | |||
Whole hospital | 21 | 24.4 | + 16.2 |
ICU | 84.3 | 83.3 | − 1.2 |